COMPASS THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-66.5M | $-49.4M | $-42.5M | $-39.2M | $-82.2M | $-29.5M | $-34.7M |
| Depreciation & Amortization | $276.0K | $589.0K | $699.0K | $782.0K | $600.0K | $2.4M | $2.1M |
| Depreciation | $300.0K | $600.0K | $700.0K | $800.0K | $600.0K | — | — |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $8.4M | $8.6M | $6.1M | $5.3M | $4.0M | $4.0M | $915.0K |
| Net Cash from Operating Activities | $-49.1M | $-44.9M | $-40.6M | $-34.1M | $-19.7M | $-26.8M | $-31.7M |
| Investing Activities | |||||||
| Capital Expenditures | $25.0K | $44.0K | $30.0K | $212.0K | $1.6M | $106.0K | $466.0K |
| Business Acquisitions | — | — | — | $0 | $318.0K | — | — |
| Net Cash from Investing Activities | $-93.3M | $46.8M | $27.0M | $-151.2M | $-1.8M | $38.0K | $-466.0K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $129.6M | $17.3M | $2.9M | $75.8M | $118.6M | $48.5M | $37.6K |
| Net Change in Cash | $-12.8M | $19.3M | $-10.7M | $-109.6M | $97.2M | $21.8M | $-32.2M |
| Free Cash Flow | $-49.2M | $-44.9M | $-40.6M | $-34.3M | $-21.2M | $-26.9M | $-32.2M |